keyword
MENU ▼
Read by QxMD icon Read
search

Lymphocytic leukemia

keyword
https://www.readbyqxmd.com/read/29040031/prospective-randomized-double-blind-phase-iii-clinical-trial-of-anti-t-lymphocyte-globulin-to-assess-impact-on-chronic-graft-versus-host-disease-free-survival-in-patients-undergoing-hla-matched-unrelated-myeloablative-hematopoietic-cell-transplantation
#1
Robert J Soiffer, Haesook T Kim, Joseph McGuirk, Mitchell E Horwitz, Laura Johnston, Mrinal M Patnaik, Witold Rybka, Andrew Artz, David L Porter, Thomas C Shea, Michael W Boyer, Richard T Maziarz, Paul J Shaughnessy, Usama Gergis, Hana Safah, Ran Reshef, John F DiPersio, Patrick J Stiff, Madhuri Vusirikala, Jeff Szer, Jennifer Holter, James D Levine, Paul J Martin, Joseph A Pidala, Ian D Lewis, Vincent T Ho, Edwin P Alyea, Jerome Ritz, Frank Glavin, Peter Westervelt, Madan H Jagasia, Yi-Bin Chen
Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We report a prospective, double-blind phase III trial to investigate the effect of ATLG (Neovii Biotech, Lexington, MA) on cGVHD-free survival. Patients and Methods Two hundred fifty-four patients 18 to 65 years of age with acute leukemia or myelodysplastic syndrome who underwent myeloablative HLA-matched unrelated hematopoietic cell transplantation (HCT) were randomly assigned one to one to placebo (n =128 placebo) or ATLG (n = 126) treatment at 27 sites...
October 17, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/29036040/frontline-management-of-chronic-lymphocytic-leukemia
#2
Richard R Furman
No abstract text is available yet for this article.
August 2017: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29035453/immunophenotyping-of-chronic-lymphocytic-leukemia
#3
Mesude Falay And Gulsum Ozet
BACKGROUND: Chronic Lymphocytic Leukemia (CLL) is one of the most common diagnoses made by flow cytometry laboratories. There is no consensus on which markers need to be used in flow cytometry for accurate immunophenotyping. Herein, we investigated the role of markers used in flow cytometry in the distinction between CLL and MCL. METHODS: A total 339 recently diagnosed B lymphoproliferative patient cases were retrospectively studied for their immunophenotypical propoerties using flow cytometry...
October 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/29035445/expression-of-leukocytic-syncytin-1-in-b-cell-acute-lymphoblastic-leukemia-and-acute-myeloid-leukemia-patients
#4
Yi Sun, Hongyan Zhu, Jianxin Song, Yaxian Jiang, Hongmei Ouyang, Ting Dong, Rui Tao, Xin Fan, Guiqian Zhang
BACKGROUND: Syncytin-1 is improperly expressed in several cancers. However, its expression profile across leukocytes in leukemia patients has not yet been analyzed. METHODS: A total of 50 AML cases and 14 B-cell ALL patients were consecutively recruited. Bone marrow samples were subjected to flow cytometry. Statistical analysis was applied to compare syncytin-1 expression between B-cell ALL and AML across granulocytes, leukemia cells, and T-lymphocytes (including CD3+, CD4+, and CD8+ subsets thereof) and to correlate syncytin-1 expression to leukemia cells and lymphocytes with the T-cell subset percentages...
October 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/29034364/microenvironmental-agonists-generate-de-novo-phenotypic-resistance-to-combined-ibrutinib-plus-venetoclax-in-cll-and-mcl
#5
Kallesh D Jayappa, Craig A Portell, Vicki L Gordon, Brian J Capaldo, Stefan Bekiranov, Mark J Axelrod, L Kyle Brett, Julia D Wulfkuhle, Rosa I Gallagher, Emanuel F Petricoin, Timothy P Bender, Michael E Williams, Michael J Weber
De novo resistance and rapid recurrence often characterize responses of B-cell malignancies to ibrutinib (IBR), indicating a need to develop drug combinations that block compensatory survival signaling and give deeper, more durable responses. To identify such combinations, we previously performed a combinatorial drug screen and identified the Bcl-2 inhibitor venetoclax (VEN) as a promising partner for combination with IBR in Mantle Cell Lymphoma (MCL). We have opened a multi-institutional clinical trial to test this combination...
June 13, 2017: Blood Advances
https://www.readbyqxmd.com/read/29034341/paclitaxel-induces-stathmin-1-phosphorylation-microtubule-stability-and-apoptosis-in-acute-lymphoblastic-leukemia-cells
#6
João Agostinho Machado-Neto, Ana Paula Nunes Rodrigues Alves, Jaqueline Cristina Fernandes, Juan Luiz Coelho-Silva, Renata Scopim-Ribeiro, Bruna Alves Fenerich, Fernanda Borges da Silva, Priscila Santos Scheucher, Belinda Pinto Simões, Eduardo Magalhães Rego, Fabiola Traina
Acute lymphoblastic leukemia (ALL) is a hematological malignancy characterized by abnormal proliferation and accumulation of lymphoblasts in the hematopoietic system. Stathmin 1 is a proliferation marker for normal lymphocytes, which has been described as highly expressed in ALL patients and functionally important for leukemia phenotype. In the present study, we expand our previous observations and aim to investigate Stathmin 1 expression and its impact on laboratory features and clinical outcomes in an independent cohort of ALL patients, and to verify the effects of paclitaxel treatment on Stathmin 1 phosphorylation and cell viability in ALL cell lines...
September 2017: Heliyon
https://www.readbyqxmd.com/read/29034060/activation-of-the-aryl-hydrocarbon-receptor-and-risk-of-lymphoma-subtypes
#7
Sonia Sanna, Giannina Satta, Marina Padoan, Sara Piro, Angela Gambelunghe, Lucia Miligi, Giovanni Maria Ferri, Corrado Magnani, Giacomo Muzi, Luigi Rigacci, Maria Giuseppina Cabras, Emanuele Angelucci, Gian Carlo Latte, Attilio Gabbas, Maria Grazia Ennas, Pierluigi Cocco
The aryl hydrocarbon receptor (AhR) is a transcription factor implicated in several pathways known to be relevant in lymphomagenesis. Aim of our study was to explore the link between AhR activation and risk of lymphoma subtypes. We used a Dual-Luciferase Assay(®) and a luminometer to detect the activation of the luciferase gene, in HepG2 cells transfected with a specific reporter systems, by a 50 ml serum aliquot of cases of diffuse large B cell lymphoma (N = 108), follicular lymphoma (N = 85), chronic lymphocytic leukemia (N = 72), multiple myeloma (N = 80), and Hodgkin lymphoma (N = 94) and 357 controls who participated in the multicentre Italian study on gene-environment interactions in lymphoma etiology (ItGxE)...
2017: International Journal of Molecular Epidemiology and Genetics
https://www.readbyqxmd.com/read/29033428/the-efficacy-of-reduced-dose-dasatinib-as-a-subsequent-therapy-in-patients-with-chronic-myeloid-leukemia-in-the-chronic-phase-the-ld-cml-study-of-the-kanto-cml-study-group
#8
Noriyoshi Iriyama, Ohashi Kazuteru, Satoshi Hashino, Shinya Kimura, Chiaki Nakaseko, Hina Takano, Masayuki Hino, Michihiro Uchiyama, Satoshi Morita, Junichi Sakamoto, Hisashi Sakamaki, Koiti Inokuchi
Objective The aim of this study was to prospectively investigate the efficacy and safety profiles of low-dose dasatinib therapy (50 mg once daily). Methods Patients with chronic myeloid leukemia in the chronic phase (CML-CP) who were being treated with low-dose imatinib (≤200 mg/day), but were resistant to this agent were enrolled in the current study (referred to as the LD-CML study). Results There subjects included 9 patients (4 men and 5 women); all were treated with dasatinib at a dose of 50 mg once daily...
October 16, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29032719/improved-survival-outcomes-with-the-addition-of-rituximab-to-initial-therapy-for-chronic-lymphocytic-leukemia-a-comparative-effectiveness-analysis-in-the-province-of-british-columbia-canada
#9
Lauren J Lee, Cynthia L Toze, Steven J T Huang, Tanya L Gillan, Joseph M Connors, Laurie H Sehn, Helene Bruyere, Heather Leitch, Khaled M Ramadan, Alina S Gerrie
Chemoimmunotherapy with rituximab improves survival in clinical trials in upfront chronic lymphocytic leukemia (CLL) treatment. This study compared clinical outcomes with and without rituximab added to first-line chemotherapy in a provincial cohort of CLL patients. Between 1973 and 2014, 1345 patients received CLL treatment: 48% with rituximab, 52% chemotherapy alone. Median overall survival (OS) and treatment-free survival (TFS) were significantly longer with rituximab: OS 8.9 vs. 6.2 years, p < .0001; TFS 3...
October 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29032274/assessment-of-impact-of-human-leukocyte-antigen-hla-type-on-outcomes-of-allogeneic-hematopoietic-stem-cell-transplant-for-chronic-lymphocytic-leukemia-cll
#10
Brian T Hill, Kwang Woo Ahn, Zhen-Huan Hu, Mahmoud Aljurf, Amer Beitinjaneh, Jean-Yves Cahn, Jan Cerny, Mohamed A Kharfan-Dabaja, Siddhartha Ganguly, Nilanjan Ghosh, Michael R Grunwald, Yoshihiro Inamoto, Tamila Kindwall-Keller, Taiga Nishihori, Richard F Olsson, Ayman Saad, Matthew Seftel, Sachiko Seo, Jeffrey Szer, Martin Tallman, Celalettin Ustun, Peter H Wiernik, Richard T Maziarz, Matt Kalaycio, Edwin Alyea, Uday Popat, Ronald Sobecks, Wael Saber
Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with many highly effective therapies. Chemorefractory disease, often characterized by deletion of chromosome 17p, has historically been associated with very poor outcomes, leading to the application of allogeneic hematopoietic stem cell transplant (allo-HCT) for medically fit patients. Although the use of allo-HCT has reduced since the introduction of novel targeted therapy for the treatment of CLL, there remains significant interest in understanding factors that may influence the efficacy of allo-HCT as it represents the only known curative treatment for CLL...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29032264/building-a-safer-and-faster-car-seatbelts-airbags-and-crispr
#11
REVIEW
Miguel-Angel Perales, Partow Kebriaei, Leslie S Kean, Michel Sadelain
Therapeutic T cell engineering has recently garnered widespread interest owing to the success of CD19 (Chimeric Antigen Receptor) CAR therapy. CARs are synthetic receptors for antigen that redirect the specificity and reprogram the function of the T cells in which they are genetically introduced. CARs targeting CD19, a cell surface molecule found in most leukemias and lymphomas, have yielded high remission rates in patients with chemorefractory, relapsed disease, including acute lymphoblastic leukemia, chronic lymphocytic leukemia and non-Hodgkin lymphoma...
October 12, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/29029465/alterations-in-dna-methylation-demethylation-intermediates-predict-clinical-outcome-in-chronic-lymphocytic-leukemia
#12
Cristina Bagacean, Adrian Tempescul, Christelle Le Dantec, Anne Bordron, Audrey Mohr, Hussam Saad, Valerie Olivier, Mihnea Zdrenghea, Victor Cristea, Pierre-François Cartron, Nathalie Douet-Guilbert, Christian Berthou, Yves Renaudineau
Cytosine derivative dysregulations represent important epigenetic modifications whose impact on the clinical outcome in chronic lymphocytic leukemia (CLL) is incompletely understood. Hence, global levels of 5-methylcytosine (5-mCyt), 5-hydroxymethylcytosine (5-hmCyt), 5-carboxylcytosine (5-CaCyt) and 5-hydroxymethyluracil were tested in purified B cells from CLL patients (n = 55) and controls (n = 17). The DNA methylation 'writers' (DNA methyltransferases [DNMT1/3A/3B]), 'readers' (methyl-CpG-binding domain [MBD2/4]), 'editors' (ten-eleven translocation [TET1/2/3]) and 'modulators' (SAT1) were also evaluated...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029444/the-prohibitin-protein-complex-promotes-mitochondrial-stabilization-and-cell-survival-in-hematologic-malignancies
#13
Jeremy A Ross, Elisa Robles-Escajeda, Derrick M Oaxaca, Diana L Padilla, Robert A Kirken
Prohibitins (PHB1 and PHB2) have been proposed to play important roles in cancer development and progression, however their oncogenic mechanism of action has not been fully elucidated. Previously, we showed that the PHB1 and PHB2 protein complex is required for mitochondrial homeostasis and survival of normal human lymphocytes. In this study, novel evidence is provided that indicates mitochondrial prohibitins are overexpressed in hematologic tumor cells and promote cell survival under conditions of oxidative stress...
September 12, 2017: Oncotarget
https://www.readbyqxmd.com/read/29029365/eighteen-month-lamivudine-prophylaxis-on-preventing-occult-hepatitis-b-virus-hbv-infection-reactivation-in-patients-with-hematologic-malignancies-receiving-immunosuppression-therapy
#14
Aldo Marrone, Nicolina Capoluongo, Chiara D'Amore, Mariantonietta Pisaturo, Mariarosaria Esposito, Salvatore Guastafierro, Isabella Siniscalchi, Margherita Macera, Adriana Boemio, Lorenzo Onorato, Luca Rinaldi, Carmine Minichini, Luigi Elio Adinolfi, Evangelista Sagnelli, Lucia Mastrullo, Nicola Coppola
This study evaluated the long-term efficacy and safety of an 18-month lamivudine prophylaxis in 68 HBsAg-negative/anti-HBc-positive patients with onco-hematological disease. All 68 consecutive HBsAg-negative/anti-HBc-positive patients with an onco-hematological disease and naïve for chemotherapy observed from April 2008 to December 2012 at two Hematology Units in Naples were treated with lamivudine for 18 months after stopping chemotherapy and monitored for HBsAg at months 1 and 3 during chemotherapy and then every three months after its discontinuation...
October 13, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29025588/trisomy-12-assessment-by-conventional-fluorescence-in-situ-hybridization-fish-fish-in-suspension-fish-is-and-laser-scanning-cytometry-lsc-in-chronic-lymphocytic-leukemia
#15
Cuc H Do, Karen M Lower, Cindy Macardle, Bryone J Kuss
Chronic lymphocytic leukemia (CLL) has an extremely heterogeneous clinical course, and prognostication is based on common genetic abnormalities which are detected by standard cytogenetic methods. However, current methods are restricted by the low number of cells able to be analyzed, resulting in the potential to miss clinically relevant sub-clonal populations of cells. A novel high throughput methodology called fluorescence in situ hybridization in suspension (FISH-IS) incorporates a flow cytometry-based imaging approach with automated analysis of thousands of cells...
October 2017: Cancer Genetics
https://www.readbyqxmd.com/read/29024486/development-of-locus-specific-sub-clone-separation-by-fluorescence-in-situ-hybridization-in-suspension-in-chronic-lymphocytic-leukemia
#16
Cuc H Do, Sheree Bailey, Cindy Macardle, Lauren A Thurgood, Karen M Lower, Bryone J Kuss
Intra-tumor genetic heterogeneity is a hallmark of cancer. The ability to monitor and analyze these sub-clonal cell populations can be considered key to successful treatment, particularly in the modern era of targeted therapies. Although advances in sequencing technologies have significantly improved our ability to analyze the mutational landscape of tumors, this utility is reduced when considering small, but clinically significant sub-clones, that is, those representing <10% of the tumor burden. We have developed a high-throughput method that utilizes a 17-probe labeled bacterial artificial chromosome contig to quantify sub-clonal populations of cells based on deletion of a single locus...
October 11, 2017: Cytometry. Part A: the Journal of the International Society for Analytical Cytology
https://www.readbyqxmd.com/read/29024461/reproducible-diagnosis-of-chronic-lymphocytic-leukemia-by-flow-cytometry-an-european-research-initiative-on-cll-eric-european-society-for-clinical-cell-analysis-escca-harmonisation-project
#17
Andy C Rawstron, Karl-Anton Kreuzer, Asha Soosapilla, Martin Spacek, Olga Stehlikova, Peter Gambell, Neil McIver-Brown, Neus Villamor, Katherina Psarra, Maria Arroz, Raffaella Milani, Javier de la Serna, M Teresa Cedena, Ozren Jaksic, Josep Nomdedeu, Carol Moreno, Gian Matteo Rigolin, Antonio Cuneo, Preben Johansen, Hans E Johnsen, Richard Rosenquist, Carsten Utoft Niemann, Wolfgang Kern, David Westerman, Marek Trneny, Stephen Mulligan, Michael Doubek, Sarka Pospisilova, Peter Hillmen, David Oscier, Michael Hallek, Paolo Ghia, Emili Montserrat
The diagnostic criteria for CLL rely on morphology and immunophenotype. Current approaches have limitations affecting reproducibility and there is no consensus on the role of new markers. The aim of this project was to identify reproducible criteria and consensus on markers recommended for the diagnosis of CLL. ERIC/ESCCA members classified 14 of 35 potential markers as "required" or "recommended" for CLL diagnosis, consensus being defined as >75% and >50% agreement, respectively. An approach to validate "required" markers using normal peripheral blood was developed...
October 10, 2017: Cytometry. Part B, Clinical Cytometry
https://www.readbyqxmd.com/read/28994094/novel-prognostic-molecular-factors-a-quantum-leap-in-the-field-of-chronic-lymphocytic-leukemia
#18
Ewelina Zakrzewska, Marta Pirog, Joanna Purkot, Krzysztof Giannopoulos
Cytogenetic lesions do not completely explain clinical heterogeneity of chronic lymphocytic leukemia (CLL). The 2016 revision of the World Health Organization classification 2008 introduced that molecular lesions of TP53, NOTCH1, SF3B1 and BIRC3 have potential clinical relevance and could be integrated into an updated risk profile. The negative clinical implications of TP53 disruptions are well constituted and patients with these mutations should be considered for novel, small molecule signal transduction inhibitors therapies...
October 10, 2017: Folia Histochemica et Cytobiologica
https://www.readbyqxmd.com/read/28993409/malt1-inhibition-is-efficacious-in-both-na%C3%A3-ve-and-ibrutinib-resistant-chronic-lymphocytic-leukemia
#19
Nakhle S Saba, Deanna H Wong, Georges Tanios, Jessica R Iyer, Patricia Lobelle-Rich, Eman L Dadashian, Delong Liu, Lorena Fontan, Erik K Flemington, Cydney M Nichols, Chingiz Underbayev, Hana Safah, Ari Melnick, Adrian Wiestner, Sarah E M Herman
The clinical efficacy displayed by ibrutinib in chronic lymphocytic leukemia (CLL) has been challenged by the frequent emergence of resistant clones. The ibrutinib target, Bruton's tyrosine kinase (BTK), is essential for B cell receptor signaling, and most resistant cases carry mutations in BTK or PLCG2, a downstream effector target of BTK. Recent findings show that MI-2, a small molecule inhibitor of the para-caspase MALT1, is effective in preclinical models of another type of BCR pathway-dependent lymphoma...
October 9, 2017: Cancer Research
https://www.readbyqxmd.com/read/28992681/ofatumumab-monoclonal-antibody-affinity-maturation-through-in-silico-modeling
#20
Zahra Payandeh, Masoumeh Rajabibazl, Yousef Mortazavi, Azam Rahim-Pour, Amir Hossein Taromchi
Background: Ofatumumab, an anti-CD20 mAb, was approved in 2009 for the treatment of chronic lymphocytic leukemia. This mAb acts through immune-mediated mechanisms, in particular complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity by natural killer cells as well as antibody-dependent phagocytosis by macrophages. Apoptosis induction is another mechanism of this antibody. Computational docking is the method of predicting the conformation of an antibody-antigen from its separated elements...
October 10, 2017: Iranian Biomedical Journal
keyword
keyword
20449
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"